Seattle-based Blaze Bioscience has raised an $8.5 million Series A from individual investors, including doctors and biotech professionals, GeekWire reports. The company is currently developing what it calls “tumor paint,” which allows doctors to view cancerous cells so they are better able to remove them from the body.

[Source: GeekWire]